Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Safusidenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023640173/en/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer

    07 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007470241/en

    BUSINESSWIRE
    07 Oct 2024
    Share Share
    AnHeart Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib
    AnHeart Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib

    07 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230907994674/en

    BUSINESSWIRE
    07 Sep 2023
    Share Share